Rahul Sahgal – CEO, Swiss-American Chamber of Commerce
Rahul Sahgal brings over 20 years of experience in both the private sector and government to his role as CEO of the Swiss-American Chamber of Commerce, uniquely positioning him to…
The Swiss-American Chamber of Commerce plays a vital and active role in assisting Swiss companies in the United States and U.S. companies in Switzerland to expand their business. The Swiss-American Chamber of Commerce is a not-for-profit organization.
Relations between Switzerland and the United States of America are extremely diverse and enjoy a rich tradition. The United States is the second largest export market for Switzerland and an important hub for education and research. Over the last 12 years, exports to America have doubled in volume, going from 10.6 to 14.5 percent of all Swiss exports between 2004 and today. Swiss pharmaceutical exports account for approximately 47 percent of trade with America.
Contact
Talacker 41, 8001 Zurich, Switzerland, Phone: +41 43 443 72 00
Rahul Sahgal brings over 20 years of experience in both the private sector and government to his role as CEO of the Swiss-American Chamber of Commerce, uniquely positioning him to…
In a wide-ranging conversation, Martin Naville of AmCham Switzerland looks at the evolution of the Switzerland-US trade relationship and the importance of pharma within it, the pressing need for a…
Martin Naville, CEO of the Swiss-American Chamber of Commerce, discusses Swiss exports to the US, global competitiveness and innovation rankings, and why the Swiss-US relationship will only continue to grow…
Johnson & Jonhson’s interest in taking over the Swiss biotech group Actelion has been confirmed, with the Wall Street Journal estimating that a total takeover price could top USD 20…
Developing manufacturing capacity for as yet unapproved drugs can create huge risk on innovators’ balance sheets, risk which can be mitigated by working instead with a competent CMO – a…
Specializing in ultra-rare diseases, Alexion targets patient populations of less than 20 patients per million. Christophe Bourdon discusses Alexion’s progress towards developing access for patients across the EMEA region. …
It is tempting to characterize Switzerland’s global pharma and life science hotspots as beginning and ending with Basel – home of industry giants Roche and Novartis. However, Zurich, Geneva, and…
Dr. Andrea Michael Meyer, general manager of Sanofi Genzyme Switzerland, reveals how the Swiss business has been experiencing year-on-year double-digit growth; how rare diseases was the foundation of Sanofi Genzyme´s…
Bernhard Neidhart, head of Office for Economy and Labor in Zug, introduces us to the Canton of Zug and explains how the region became a hotspot for pharma. To…
For the eighth year in a row the World Economic Forum has ranked Switzerland first in both global competitiveness and in innovation; economiesuisse CEO Monika Rühl discusses the main issues…
Michelle Lock describes the positive challenges that come with expanding a biopharmaceutical business that possesses a well-regarded pipeline, and that continuously launches products across the Alpine region. She highlights the…
An increasing number of pharma MNCs are looking towards Switzerland for their European base. Despite high costs compared to elsewhere in Europe, Switzerland’s infrastructure, location, and R&D ecosystem make it…
An increasing number of pharma MNCs are looking towards Switzerland for their European base. Despite high costs compared to elsewhere in Europe, Switzerland’s infrastructure, location, and R&D ecosystem make it…
Dr. André T. Dahinden, General Manager of Amgen Switzerland, talks about their four cutting-edge products that will help drive future growth, reveals how being innovative includes partnering with payers for…
Michael Cobas Meyer of Eli Lilly Switzerland reveals how these are very exciting times for the company, particularly given an extremely rich pipeline in the areas of diabetes, oncology and…
See our Cookie Privacy Policy Here
